imipramine has been researched along with reboxetine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 15 (51.72) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Berzewski, H; Gagiano, CA; Van Moffaert, M | 1 |
| Bercoff, E; Chiu, E; Katona, C; Tack, P; Versiani, M; Woelk, H | 1 |
| Hirschfeld, RM | 1 |
| Tanum, L | 1 |
| Schatzberg, AF | 1 |
| Brunello, N; Kasper, S; Leonard, B; Mendlewicz, J; Montgomery, S; Nelson, J; Paykel, E; Racagni, G; Versiani, M | 1 |
| Holoubek, G; Müller, WE | 1 |
| Cardenas, S; Caviedes, P; Graumann, R; Martinez-Alvarado, P; Olea-Azar, C; Paris, I; Perez-Pastene, C; Raisman-Vozari, R; Segura-Aguilar, J; Vieira, MN | 1 |
| Nevéus, T | 1 |
| Cak, HT; Cetin, FC | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Lundmark, E; Nevéus, T | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Bevins, RA; Dion, AM; Murrin, LC; Sanderson, SC | 1 |
| Arias, HR; Benson, LC; Fedorov, NB; Feuerbach, D; Gatto, GJ; Lippiello, PM; Ortells, MO | 1 |
| Młyniec, K; Nowak, G | 2 |
| Nowak, G; Pilc, A; Poleszak, E; Popik, P; Siwek, A; Szewczyk, B; Wolak, M | 1 |
| Cadeddu, R; Carboni, E; Ibba, M; Sadile, A | 1 |
| Niedzielska, E; Nowak, G; Pałucha-Poniewiera, A; Pilc, A; Pomierny, B; Pomierny-Chamioło, L; Siwek, A | 1 |
| Krakowska, A; Mlyniec, K; Nowak, G; Opoka, W; Ostachowicz, B; Reczynski, W | 1 |
| Dudka, J; Kasperek, R; Nowak, G; Poleszak, E; Serefko, A; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A | 1 |
| Gaweł, M; Młyniec, K; Nowak, G | 1 |
| Beltran, E; Domínguez-Andrés, J; Erburu, M; Mai, A; Muñoz-Cobo, I; Puerta, E; Suzuki, T; Tordera, RM; Valente, S | 1 |
| Harro, J; Kõiv, K; O'Leary, A; Raudkivi, K | 1 |
| Cirilli, R; Erburu, MM; Mai, A; Muñoz-Cobo, I; Puerta, E; Tordera, RM; Valente, S; Zwergel, C | 1 |
| Bogatko, K; Doboszewska, U; Dudka, J; Poleszak, E; Serefko, A; Świąder, K; Szopa, A; Wlaź, A; Wlaź, P; Wośko, S; Wróbel, A; Wyska, E | 1 |
| Chmielarz, P; Chorązka, K; Kowalska, M; Kuśmierczyk, J; Nalepa, I; Rafa-Zabłocka, K; Satała, G | 1 |
| Koziorowski, M; Mytych, J; Sołek, P; Tabęcka-Łonczyńska, A | 1 |
4 review(s) available for imipramine and reboxetine
| Article | Year |
|---|---|
History and evolution of the monoamine hypothesis of depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Drug Industry; History, 20th Century; Humans; Imipramine; Morpholines; Norepinephrine; Reboxetine; Receptors, Biogenic Amine; Serotonin | 2000 |
Reboxetine: tolerability and safety profile in patients with major depression.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Imipramine; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reboxetine; Therapeutic Equivalency | 2000 |
Clinical efficacy of reboxetine in major depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Controlled Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Imipramine; Morpholines; Norepinephrine; Panic Disorder; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2000 |
The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Catechol O-Methyltransferase; Depression; Humans; Imipramine; Monoamine Oxidase; Morpholines; Norepinephrine; Reboxetine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tyrosine 3-Monooxygenase | 2002 |
2 trial(s) available for imipramine and reboxetine
| Article | Year |
|---|---|
Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Pressure; Depressive Disorder; Double-Blind Method; Electrocardiography; Female; Headache; Humans; Imipramine; Male; Middle Aged; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Xerostomia | 1997 |
Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial.
Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Female; Geriatric Psychiatry; Humans; Hypotension; Imipramine; Male; Morpholines; Reboxetine; Treatment Outcome | 1999 |
23 other study(ies) available for imipramine and reboxetine
| Article | Year |
|---|---|
Specific modulation of sigma binding sites by the anxiolytic drug opipramol.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Brain; Cell Membrane; Citalopram; Imipramine; Male; Morpholines; Opipramol; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Adrenergic, beta; Receptors, Serotonin, 5-HT2; Receptors, sigma; Swimming | 2003 |
Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Catecholamine Plasma Membrane Transport Proteins; Cell Death; Cells, Cultured; Chlorides; Dicumarol; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Embryo, Mammalian; Enzyme Inhibitors; Ferric Compounds; Fluorescent Antibody Technique; Imipramine; Indolequinones; Iron; Iron Isotopes; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Microscopy, Confocal; Models, Biological; Morpholines; Nerve Tissue Proteins; Neurons; Nomifensine; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Rats; Rats, Inbred F344; Rats, Wistar; Reboxetine; Serotonin Plasma Membrane Transport Proteins; Sodium; Substantia Nigra; Symporters; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2005 |
Reboxetine in therapy-resistant enuresis: results and pathogenetic implications.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Child; Cohort Studies; Congenital Abnormalities; Deamino Arginine Vasopressin; Disabled Children; Dose-Response Relationship, Drug; Drug Administration Schedule; Enuresis; Female; Follow-Up Studies; Humans; Imipramine; Male; Morpholines; Probability; Prospective Studies; Quality of Life; Reboxetine; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2006 |
Reboxetine use in the treatment of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Female; Humans; Imipramine; Male; Methylphenidate; Morpholines; Reboxetine | 2006 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
Reboxetine in therapy-resistant enuresis: a retrospective evaluation.
Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Antidiuretic Agents; Child; Deamino Arginine Vasopressin; Dose-Response Relationship, Drug; Drug Resistance; Enuresis; Female; Follow-Up Studies; Humans; Imipramine; Male; Morpholines; Pilot Projects; Prognosis; Reboxetine; Retrospective Studies; Urination; Young Adult | 2009 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Diminished conditioned responding to the nicotine stimulus by antidepressant drugs with differing specificity for the serotonin and norepinephrine transporter.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Discrimination Learning; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Generalization, Response; Imipramine; Male; Morpholines; Nicotine; Nicotinic Agonists; Norepinephrine Plasma Membrane Transport Proteins; Random Allocation; Rats; Rats, Sprague-Dawley; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tobacco Use Disorder | 2012 |
Functional and structural interaction of (-)-reboxetine with the human α4β2 nicotinic acetylcholine receptor.
Topics: Adrenergic Uptake Inhibitors; Alkaloids; Animals; Azocines; Bridged Bicyclo Compounds, Heterocyclic; Calcium; Dose-Response Relationship, Drug; Electrophysiological Phenomena; Epithelial Cells; HEK293 Cells; Humans; Imipramine; Models, Molecular; Molecular Conformation; Morpholines; Nicotinic Agonists; Patch-Clamp Techniques; Pyridines; Quinolizines; Radioligand Assay; Reboxetine; Receptors, Nicotinic; Torpedo | 2013 |
GPR39 up-regulation after selective antidepressants.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Citalopram; Imipramine; Male; Mice; Morpholines; Reboxetine; Receptors, G-Protein-Coupled; Up-Regulation; Zinc | 2013 |
Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test.
Topics: 2-Amino-5-phosphonovalerate; Animals; Antidepressive Agents; Citalopram; Cyclopropanes; Imipramine; Immobility Response, Tonic; Male; Mice; Milnacipran; Morpholines; Motor Activity; N-Methylaspartate; Oxazines; Quinoxalines; Reboxetine; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate | 2013 |
Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: a possible role in antidepressant therapy?
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Citalopram; Desipramine; Dopamine; Dose-Response Relationship, Drug; Fluoxetine; Imipramine; Male; Morpholines; Norepinephrine; Rats, Sprague-Dawley; Reboxetine; Septal Nuclei; Time Factors | 2014 |
Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors.
Topics: Animals; Antidepressive Agents; Blotting, Western; Brain; Cerebral Cortex; Citalopram; Excitatory Amino Acid Antagonists; Hippocampus; Imipramine; Male; Moclobemide; Morpholines; Pyridines; Radioligand Assay; Rats, Wistar; Reboxetine; Receptor, Metabotropic Glutamate 5; Thiazoles; Tritium | 2014 |
Chronic but not acute antidepresant treatment alters serum zinc/copper ratio under pathological/zinc-deficient conditions in mice.
Topics: Animals; Antidepressive Agents; Bupropion; Citalopram; Copper; Depression; Disease Models, Animal; Imipramine; Male; Mice; Morpholines; Reboxetine; Sodium Chloride; Zinc | 2014 |
The effects of ifenprodil on the activity of antidepressant drugs in the forced swim test in mice.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Drug Synergism; Fluoxetine; Imipramine; Mice; Morpholines; Piperidines; Reboxetine; Swimming; Thiazepines | 2014 |
Study of antidepressant drugs in GPR39 (zinc receptor⁻/⁻) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Imipramine; Ketamine; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Motor Activity; Psychological Tests; Reboxetine; Receptors, G-Protein-Coupled; Receptors, N-Methyl-D-Aspartate; Swimming | 2015 |
Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity.
Topics: Adult; Animals; Antidepressive Agents; Chronic Disease; Depressive Disorder; Fluoxetine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imipramine; Male; Mice, Inbred C57BL; Middle Aged; Morpholines; Neuronal Plasticity; Prefrontal Cortex; Reboxetine; RNA, Messenger; Sirtuins; Stress, Psychological | 2015 |
Up-regulation of the GPR39 Zn2+-sensing receptor and CREB/BDNF/TrkB pathway after chronic but not acute antidepressant treatment in the frontal cortex of zinc-deficient mice.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Bupropion; Citalopram; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Drug Administration Schedule; Frontal Lobe; Imipramine; Male; Mice; Morpholines; Reboxetine; Receptor, trkB; Receptors, G-Protein-Coupled; Signal Transduction; Up-Regulation; Zinc | 2015 |
Antidepressants differentially affect striatal amphetamine-stimulated dopamine and serotonin release in rats with high and low novelty-oriented behaviour.
Topics: Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Corpus Striatum; Dopamine; Fluoxetine; Imipramine; Male; Microdialysis; Morpholines; Rats; Rats, Wistar; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2016 |
Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers.
Topics: Animals; Antidepressive Agents; Down-Regulation; Epigenesis, Genetic; Fluoxetine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imipramine; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Prefrontal Cortex; Random Allocation; Reboxetine; Sirtuin 2 | 2018 |
DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests.
Topics: Adenosine A1 Receptor Antagonists; Animals; Antidepressive Agents; Brain; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Hindlimb Suspension; Imipramine; Male; Mice; Motor Activity; Reboxetine; Serotonin Antagonists; Xanthines | 2018 |
Antidepressants Differentially Regulate Intracellular Signaling from α1-Adrenergic Receptor Subtypes In Vitro.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Fluoxetine; Gene Expression Regulation; Humans; Imipramine; Mianserin; Mice; PC12 Cells; Rats; Reboxetine; Receptors, Adrenergic, alpha-1; Signal Transduction | 2021 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antipsychotic Agents; Cell Line; Escitalopram; Fluoxetine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Imipramine; Male; Mice; Micronuclei, Chromosome-Defective; Mirtazapine; Models, Biological; Olanzapine; Organ Specificity; Reboxetine; Reproduction; Signal Transduction; Spermatogenesis; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Time Factors; Venlafaxine Hydrochloride | 2021 |